Self-assembling Peptide Barriers for Local Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical regimens for managing inflammation, such as steroids and non-steroidal anti-inflammatory drugs, often come with undesirable side effects and fail to effectively mitigate chronic inflammatory disorders and autoimmune diseases.
Innovation Solution
Compositions of self-assembling peptides and peptidomimetics that can be applied directly to inflammation sites, assembling upon contact with bodily fluids to form a barrier that reduces inflammation symptoms like pain, swelling, and immune response dysregulation, while potentially including therapeutic agents for enhanced healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If steroids and non-steroidal anti-inflammatory drugs are used to manage inflammation, then inflammation symptoms are reduced, but serious side effects occur such as Cushing's syndrome and gastric ulcerations
Solution Approach 1:
The patent uses self-assembling peptides as intermediary substances that modulate the inflammatory response through natural biological pathways rather than direct suppression. These peptides act as mediators between the immune system and inflammatory processes, providing anti-inflammatory effects without the harsh side effects of conventional drugs by engaging in specific protein-protein interactions and regulating cytokine production naturally.
Solution Approach 2:
The invention changes the fundamental parameter of anti-inflammatory treatment from using small-molecule synthetic drugs with broad non-specific suppression to using biocompatible self-assembling peptides with specific targeted action. This parameter change includes transitioning from systemic administration with high bioavailability to localized delivery with controlled release, fundamentally altering the therapeutic index and side effect profile.
2Object-affected harmful factors
If conventional anti-inflammatory drugs are applied systemically, then inflammation is suppressed, but the drugs fail to effectively mitigate chronic inflammatory disorders and autoimmune diseases
Solution Approach 1:
The self-assembling peptides are designed to pre-assemble into nanofiber networks that can be loaded with therapeutic agents before administration. This preliminary structuring allows the composition to form a localized reservoir at the application site, enabling sustained release and prolonged therapeutic action necessary for treating chronic inflammatory disorders and autoimmune diseases where long-term suppression is required.
Solution Approach 2:
The patent employs dynamic self-assembling peptides that can reversibly change their assembly state in response to physiological conditions. This dynamic behavior allows the therapeutic composition to adapt to the chronic inflammatory environment, maintaining therapeutic efficacy over extended periods while responding to changes in the disease state, thereby improving reliability for chronic disorder management.
3Object-generated harmful factors
If self-assembling peptides are applied locally to inflammation sites, then systemic side effects are avoided, but the compositions require precise assembly control upon contact with bodily fluids
Solution Approach 1:
The self-assembling peptides are designed to autonomously assemble into functional nanofiber structures upon contact with bodily fluids without requiring external control mechanisms. The peptides contain intrinsic self-assembly motifs that respond to physiological conditions such as pH, ionic strength, and protein interactions, enabling them to self-organize into therapeutic delivery vehicles automatically at the application site, thereby eliminating the need for complex external assembly control systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The self-assembling peptides effectively reduce inflammation symptoms without systemic side effects, enhance tissue healing, and can be formulated for topical or internal administration, offering a safer alternative for managing chronic inflammatory disorders and autoimmune diseases.
Implementation Method 1
Compositions of self-assembling peptides and peptidomimetics that can be applied directly to inflammation sites, assembling upon contact with bodily fluids to form a barrier
Data Source
AI summary
Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat inflammation or inflammatory diseases, or reduce one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAP for local administration to a site of inflammation for reduction or prevention of symptoms of inflammatory diseases and disorders are described. The compositions include one or more SAP in an amount and concentration effective to reduce or prevent one or more symptoms of undesirable inflammation. The SAP can assemble prior to or after the composition is administered. The SAP form a structure within or at the surface of the body that prevents and/or reduces symptoms associated with inflammation and other dysregulated immune processes. The peptides can assemble upon contact with bodily fluids (e.g., synovial fluid), or can be contacted with ionic solutions to initiate assembly.